Premium
Pharmacokinetics of dinalbuphine sebacate and nalbuphine in human after intramuscular injection of dinalbuphine sebacate in an extended‐release formulation
Author(s) -
Tien Yu en,
Huang WenChuan,
Kuo HuiYuan,
Tai Lily,
Uang YowShieng,
Chern Wendy H.,
Huang JinDing
Publication year - 2017
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.2088
Subject(s) - nalbuphine , medicine , pharmacology , anesthesia , pharmacokinetics , intramuscular injection , chemistry , opioid , receptor
Nalbuphine is a semi‐synthetic opioid indicated for the relief of moderate to severe pain. Its short half‐life requires frequent injections in clinical practice, resulting in a greater incidence of adverse events. A prodrug of nalbuphine has been developed, dinalbuphine sebacate (DNS), dissolved in a simple oil‐based injectable formulation, which could deliver and maintain an effective blood level of nalbuphine. An open‐label, prospective, two‐period study was performed in healthy volunteers to verify the extended blood concentration profile of nalbuphine. Twelve healthy Taiwanese were randomized to receive an intramuscular injection of 20 mg nalbuphine HCl and 150 mg DNS sequentially with a washout period of 5 days. To prevent DNS hydrolysis during sample analysis, the effect of four esterase inhibitors was evaluated in the quantitation of DNS in human whole blood and thenoyltrifluoroacetone was chosen. The bioavailability of nalbuphine from intramuscularly injected DNS relative to that from nalbuphine HCl was 85.4%. The mean absorption time of nalbuphine from DNS was 145.2 h. It took approximately 6 days for the complete release of DNS into the blood stream where DNS was rapidly hydrolysed to nalbuphine; suggesting a single injection of 150 mg DNS in our extended‐release formulation could provide long‐lasting pain relief.